A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Investigate the Safety of CAL-263 in Allergic Rhinitis Subjects and Effects on the Response to Environmental Chamber Allergen Challenge.
Phase of Trial: Phase I
Latest Information Update: 04 May 2011
At a glance
- Drugs CAL 263 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Adverse reactions
- 23 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Feb 2010 New trial record